Stock Falling

when i starred at Radius the stock was at almost 60.00, the market is at a record high and Radius is now at 18.19 enough said.

 

Enough said except they’ll be more to say of it continues to tank, which is highly possible.

 

“Of” it continues tank? Grammar much?

 

This company is a frog that was parading as a prince. Radius has lost it's shine with investors. Sadly, the worst is yet to come. This is going to be like watching a train wreck.

 

Any....FACTS?

 

Facts??? $60 to $18 (and still falling). Downgrades by many investment firms. Huge investor sell offs. Company had to postpone studies due to inability to fund them. What more do you need? Go back and bury your head in the sand and wait to take it up the arse, dumbass.

 

The fact is that the company is operating at a loss and doesn't expect to make it to the black anytime soon. The valuation of the company is now close to 800 Million. The problem is that the paltry sales each quarter is not exceeding the expenses. By trimming the sales force the company has signaled that this trend isn't going to change any time soon. Most companies in a growth mode don't trim sales efforts to grow sales.
Ask yourself is Radius close to winning some big contract or releasing some new data that is going to be a game changer and really boost sales? Radius overestimated the market potential of Tymlos. Wall St. isn't stupid.

 

Anothrr new 52 week low: 17.43

 

What studies were postponed?

 

they have $300M, what inability to fund them?

 

Most biotechs or biopharmas are unprofitable for years, you know that right?

 

While true, the unprofitable years are mostly during the R&D and prelaunch/commercialization years. And Not all launches are created equal, to be sure, but this company seems to have made a lot of promises they can’t keep.

 

What promises did they not keep? Not a rhetorical question, I’m curious.
Also, no, it takes years to become profitable. Sales take time to ramp up. You are right, though: not all launches are equal. Just look at RLYP, with no competition, the entire market to itself, they did less than $55M last year, against $250M of marketing.

 

Oh, well then... my mistake. If Radius will be unprofitable for years then definitely the price of the stock should be going up. My bad.

 

2018 Q2 balance sheet shows 52 Million in cash
2018 Q1 balance sheet shows 56.1 Million in cash
2017 Q4 balance sheet shows 118.6 Million in cash
2017 Q3 balance sheet shows 446.9 Million in cash

2018 Q2 balance sheet shows 357.2 in total assets although that figure seems a little high

 

2018 Q2 balance sheet shows $318M in cash.

 

Yes, your bad. You need some context, obviously, it’s better to be profitable, but can you name one biopharma that’s profitable right away? My point was: your expectations are completely unreasonable, it takes time. Get a life.

 

You think they only spent $4M during the second quarter? Then wouldn’t that make them profitable for the second quarter?

 

The reality is with the loss of exclusivity on Express Scripts and now generic forteo coming this company will never get to profitability the only hope is the oncology drug and that is a big if

 

fair enough